Immunome, Inc.
$24.25
▼
-2.72%
2026-04-21 07:29:01
immunome.com
NCM: IMNM
Explore Immunome, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.79 B
Current Price
$24.25
52W High / Low
$27.65 / $6.96
Stock P/E
—
Book Value
$5.61
Dividend Yield
—
ROCE
-35.12%
ROE
-52.09%
Face Value
—
EPS
$-2.43
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
177
Beta
2.14
Debt / Equity
0.61
Current Ratio
14.69
Quick Ratio
14.69
Forward P/E
-10.25
Price / Sales
353.21
Enterprise Value
$1.8 B
EV / EBITDA
-8.51
EV / Revenue
259.61
Rating
Strong Buy
Target Price
$35.54
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Arbutus Biopharma Corporation | $4.6 | — | $899.2 M | — | -30.53% | -38.52% | $5.1 / $2.94 | $0.4 |
| 2. | MiMedx Group, Inc. | $3.25 | 10.44 | $507.35 M | — | 22.95% | 21.61% | $7.99 / $3.31 | $1.73 |
| 3. | Fortrea Holdings Inc. | $10.44 | — | $976.14 M | — | -1.7% | -1.02% | $18.67 / $3.97 | $6.05 |
| 4. | Wave Life Sciences Ltd. | $7.58 | — | $1.43 B | — | -39.63% | -54.97% | $21.73 / $5.02 | $2.76 |
| 5. | ALX Oncology Holdings Inc. | $1.75 | — | $219.79 M | — | -292.37% | -1.46% | $2.66 / $0.4 | $0.48 |
| 6. | Mirum Pharmaceuticals, Inc. | $95.71 | — | $5.78 B | — | -3.47% | -8.65% | $109.28 / $38.22 | $6.06 |
| 7. | Contineum Therapeutics, Inc. | $13.47 | — | $524.38 M | — | -25.5% | -26.13% | $16.33 / $3.35 | $6.99 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 4.01 M | 2.93 M | 2.74 M | — |
| Operating Profit | -72.86 M | -60.14 M | -46.48 M | -44.64 M | -55.6 M | — |
| Net Profit | -69.9 M | -57.46 M | -43.4 M | -41.64 M | -80.25 M | — |
| EPS in Rs | -0.62 | -0.51 | -0.38 | -0.37 | -0.71 | -0.78 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 6.94 M | 9.04 M | 14.02 M | 0 M |
| Operating Profit | -224.11 M | -153.46 M | -28.73 M | -36.9 M |
| Net Profit | -212.39 M | -292.96 M | -106.81 M | -36.9 M |
| EPS in Rs | -1.88 | -2.59 | -0.94 | -0.33 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 683.19 M | 240.24 M | 148.54 M | 24.05 M |
| Total Liabilities | 48.84 M | 59.08 M | 28.66 M | 7.39 M |
| Equity | 634.34 M | 181.16 M | 119.88 M | 16.65 M |
| Current Assets | 660.78 M | 221.34 M | 144.7 M | 22.65 M |
| Current Liabilities | 44.99 M | 54.31 M | 21.83 M | 7.33 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -190.92 M | -110.79 M | -7.57 M | -28.69 M |
| Investing CF | 60.8 M | -85.06 M | -30.48 M | -0.25 M |
| Financing CF | 640.36 M | 240.53 M | 116.41 M | 0.03 M |
| Free CF | -206.85 M | -164.3 M | -8.4 M | -28.94 M |
| Capex | -15.93 M | -53.51 M | -0.83 M | -0.25 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -35.5% | — | — | — |
| Earnings Growth % | -174.29% | -189.48% | — | — |
| Profit Margin % | -3240.38% | -761.92% | — | — |
| Operating Margin % | -1697.33% | -204.94% | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -1674.08% | -199.74% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.